These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

98 related items for PubMed ID: 7214296

  • 21. A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant bacillus Calmette Guérin therapy?
    Rastinehad AR, Ost MC, Vanderbrink BA, Greenberg KL, El-Hakim A, Marcovich R, Badlani GH, Smith AD.
    Urology; 2009 Jan; 73(1):27-31. PubMed ID: 18929398
    [Abstract] [Full Text] [Related]

  • 22. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L, Cesson V, Lucca I, Cerantola Y, Valerio M, Fritschi U, Vlamopoulos Y, Burruni R, Legris AS, Dartiguenave F, Gharbi D, Martin V, Vaucher L, Speiser DE, Romero P, Jichlinski P, Nardelli-Haefliger D.
    Clin Cancer Res; 2017 Feb 01; 23(3):717-725. PubMed ID: 27521445
    [Abstract] [Full Text] [Related]

  • 23. Prognostic factors and risk groups in T1G3 non-muscle-invasive bladder cancer patients initially treated with Bacillus Calmette-Guérin: results of a retrospective multicenter study of 2451 patients.
    Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeckt K, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeney LA, Colombo R, Briganti A, Babjuk M, Malmström PU, Oderda M, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R, Frea B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, Shariat SF, Palou J.
    Eur Urol; 2015 Jan 01; 67(1):74-82. PubMed ID: 25043942
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Immunotherapy of carcinoma of the lung].
    Sega E, Mineo TC, Rea SR, Sega FM, Ricci C.
    Recenti Prog Med; 1978 Mar 01; 64(3):293-309. PubMed ID: 351751
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of photodynamic therapy for recurrent, high grade nonmuscle invasive bladder cancer refractory or intolerant to bacille Calmette-Guérin immunotherapy.
    Lee JY, Diaz RR, Cho KS, Lim MS, Chung JS, Kim WT, Ham WS, Choi YD.
    J Urol; 2013 Oct 01; 190(4):1192-9. PubMed ID: 23648222
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. [Tumor cell vaccination for treatment of renal cell carcinoma].
    Kriegmair M, Oberneder R.
    Urologe A; 1995 May 01; 34(3):204-7. PubMed ID: 7610513
    [Abstract] [Full Text] [Related]

  • 31. Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer.
    Chang AE, Li Q, Jiang G, Sayre DM, Braun TM, Redman BG.
    J Clin Oncol; 2003 Mar 01; 21(5):884-90. PubMed ID: 12610189
    [Abstract] [Full Text] [Related]

  • 32. Active-specific immunotherapy for melanoma.
    Mitchell MS, Harel W, Kempf RA, Hu E, Kan-Mitchell J, Boswell WD, Dean G, Stevenson L.
    J Clin Oncol; 1990 May 01; 8(5):856-69. PubMed ID: 2139701
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K, Chihara Y, Kondo H, Hirao Y.
    Hinyokika Kiyo; 2006 Jun 01; 52(6):433-8. PubMed ID: 16848356
    [Abstract] [Full Text] [Related]

  • 36. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ.
    Semin Urol Oncol; 1996 Feb 01; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [Abstract] [Full Text] [Related]

  • 37. Insignificant role of bacillus Calmette-Guérin maintenance therapy after complete transurethral resection of bladder tumor for intermediate- and high-risk non-muscle-invasive bladder cancer: Results from a randomized trial.
    Nakai Y, Anai S, Tanaka N, Chihara Y, Haramoto M, Otani T, Nakagawa Y, Hirao Y, Konishi N, Fujimoto K.
    Int J Urol; 2016 Oct 01; 23(10):854-860. PubMed ID: 27416975
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Treatment of kidney cancer with autologous tumor cell vaccines of short-term cell lines derived from renal cell carcinoma.
    Dillman RO, Barth NM, VanderMolen LA, Garfield DH, De Leon C, O'Connor AA, Mahdavi K, Nayak SK.
    Cancer Biother Radiopharm; 2001 Feb 01; 16(1):47-54. PubMed ID: 11279797
    [Abstract] [Full Text] [Related]

  • 40. Purified Protein Derivative Skin test prior to bacillus Calmette-Guérin Therapy May have Therapeutic Impact in Patients with Nonmuscle Invasive Bladder Cancer.
    Niwa N, Kikuchi E, Matsumoto K, Kosaka T, Mizuno R, Oya M.
    J Urol; 2018 Jun 01; 199(6):1446-1451. PubMed ID: 29307686
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.